<DOC>
	<DOCNO>NCT01144377</DOCNO>
	<brief_summary>The primary objective study include evaluate dose response LY2541546 use bone mineral density ( BMD ) change baseline compare placebo , evaluate overall safety tolerability LY2541546 follow multiple subcutaneous administration postmenopausal ( PMP ) woman low BMD . Following last dose study drug , participant 's able participate 12 month extension collect additional safety efficacy data ( treatment administer extension ) .</brief_summary>
	<brief_title>A Study LY2541546 Women With Low Bone Mineral Density</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<criteria>Ambulatory , postmenopausal woman , inclusive . Have low bone mineral density ( BMD ) , define Tscore , equivalent BMD absolute value ( g/cm2 ) , lumbar spine 3.5 2.0 , inclusive . Without language barrier , reliable , willing make available duration study follow study procedure . Willing take study drug daily supplement ( calcium Vitamin D ) . Normal laboratory test laboratory test result determine clinically significant investigator . Serum phosphate serum calcium must within normal limit , platelet level great 100,000 mm3 . Have receive treatment follow medication recently 3 month prior screen Androgen , Calcitonin , Estrogen ( include counter preparation know estrogenic activity ) * , Progestin ( include counter preparation know progestogenic activity ) * , SERMs ( Raloxifene , Tamoxifen , Toremifene , Clomiphene ) , Tibolone Have previously use currently use denosumab , parathyroid hormone ( PTH ) and/or PTH analog , strontium ranelate , parenteral formulation bisphosphonates . Have receive treatment oral bisphosphonate within last year Have receive therapeutic dos systemic corticosteroid one month 6 month prior screen . Have receive therapeutic dos fluoride ( 20 mg/day ) 3 month last 3 year , total 2 year , within last 6 month . Have severe Vitamin D deficiency define 25hydroxyvitamin D less &lt; 9.2 ng/mL ( 23nmol/L ) screening . If serum 25hydroxyvitamin D level screen less equal 9.2 ng/mL &lt; 20 ng/mL , patient receive load dose Vitamin D ( dose approximately 100,000 IU give orally ) prior enrollment . Have know bone disorder low BMD osteoporosis . Have history osteoporotic fracture , include know prevalent vertebral fracture evidence prevalent vertebral fracture screen spine Xray dualenergy xray absorptiometry ( DXA ) , consider high risk fracture . Presence abnormality ( artifacts osteophyte ) would confound DXA evaluation lumbar vertebra L1 L4 region . Have history Bell 's palsy , cranial nerve disorder , history Temporomandibular Joint Muscle Disorders ( TMJDs ) . Have history cancer within previous 5 year , except excise superficial lesion basal cell carcinoma squamous cell carcinoma skin . Have history presence cardiovascular , respiratory , hepatic , renal , gastrointestinal , endocrine , hematological , neurological disorder capable constitute risk take study medication interfere interpretation data . Have acute chronic liver disease ( [ bilirubin &gt; 34 µmol/L &gt; 2.0 mg/dL , alanine transaminase [ ALT/SGPT ] &gt; 100 U/L , alkaline phosphatase &gt; 300 U/L ) . Have impair kidney function ( serum creatinine &gt; 135 µmol/L &gt; 2.0 mg/dL ) . Have know allergy LY2541546 , diluents excipients LY2541546 , significant allergy monoclonal antibody History excessive consumption alcohol abuse drug within last year . Have poor medical condition psychiatric risk treatment investigational drug .</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>osteoporosis</keyword>
</DOC>